San Diego-dependent Viking Therapeutics marked by itself as a significant competitor inside the weight loss drug current market in February right after revealing promising information from the mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection and in